Genmab — Juni 2020

Bulder

Flere epco-data d. 12. juni, men snapshot, så ikke om 48 mg expansion part.

E_L

The 6-month cardiac response rate was 42% for DARA-CyBorD and 22% for CyBorD (P=0.0029); 6-month renal response rate was 54% and 27%, respectively - Renal even higher as cardiac

Bulder

Den partner de "kører på" er blue chip med masser af erfaring med det hæmatologiske område. Men de får stadig nye henvendelser vedr. epco.

Bulder

De forventer at indhente Roche og Regeneron.

kkjoel

Han siger at US commercialization rights er vigtigt for "the next stage of the company".

kkjoel

Mime8 duobody med NOVO er "15 gange bedre end Hemlibra".

kkjoel

Han regenr med at have to ekstra egne molekyler i klinikken ved udgangen af året.

Bulder

Måske hører vi på eha nærmere om de 5 pts, der var på 48 mg, når det nu er valgt som RP2D.

kkjoel

Osse i EHA Andromeda abstract: "The CR rate was 53% for DARA-CyBorD and 18% for CyBorD". Kan ikke huske om tallet har været fremme her før - men 3 gange så god CR - det lyder da temmelig godt?!

kkjoel

For nu at sige det på nordjysk...

Bulder

Det stod i pressemeddelelsen forleden

E_L

on epco : up to now we still get parties reaching out to us to start conversations to partner epco but we prioritised 1, blue chip with a lot of expertise in heamophilia area

E_L

"we will surprise the market with a very sizable upfront"

E_L

very interesting indeed on PD-L1/4-1BB , but also on the Novo nordisk Duobody, did he really say 50x better as others there?

E_L

Isatuximab also has an LBA at EHA for combi with Kd

E_L

i have a feeling it will be a large auction again today...

E_L

the Amivantamab
trial ads Chemotherapy Combination Cohort https://clinicaltrials.gov/ct2/history/NCT02609776?A=45&B=46&C=merged#StudyPageTop

kkjoel

He said 15 times better than Hemlibra.. whatever that means.

kkjoel

What was the sizable upfront on? (He actually said - as Bulder mentioned 15:17 - not going after upfront, but 50/50 deals!)

E_L

ok lol thks, still a LOT better